Correlation between gut microbiota and the development of Graves' disease: A prospective study

From BugSigDB
Needs review
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI Uniform resource identifier for web resources.
Authors
Deng Y, Wang J, Xie G, Zou G, Li S, Zhang J, Cai W, Xu J
Journal
iScience
Year
2023
Keywords:
Human metabolism, Microbial physiology, Microbiome, Pathology
The association between gut microbiota and development of Graves' disease (GD) remains unclear. This study aimed to profile the gut microbiota of 65 patients newly diagnosed with GD before and after treatment and 33 physical examination personnel via 16S rRNA sequencing. Significant differences in the gut microbiota composition were observed between the two groups, showing relative bacterial abundances of 1 class, 1 order, 5 families, and 14 genera. After treatment, the abundance of the significantly enriched biota in the GD group decreased considerably, whereas that of the previously decreased biota increased considerably. Further, interleukin-17 levels decreased significantly. The random forest method was used to identify 12 genera that can distinguish patients with GD from healthy controls. Our study revealed that the gut microbiota of patients with GD exhibit unique characteristics compared with that of healthy individuals, which may be related to an imbalance in the immune system and gut microbiota.

Experiment 1


Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Subjects

Location of subjects
China
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Graves disease Basedow disease,Basedow's disease,exophthalmic goiter,Flajani-Basedow-Graves disease,grave's disease,Graves disease,Graves' disease,Graves' hyperthyroidism,parry disease,toxic diffuse goiter,graves disease
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Control group (Con)
Group 1 name Corresponds to the case (exposed) group for case-control studies
Graves’ disease (GD)
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Patients diagnosed with Graves’ disease (GD)
Group 0 sample size Number of subjects in the control (unexposed) group
33
Group 1 sample size Number of subjects in the case (exposed) group
65
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
Three months

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V3-V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
Welch's T-Test
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
Yes

Alpha Diversity

Pielou Quantifies how equal the community is numerically
unchanged
Shannon Estimator of species richness and species evenness: more weight on species richness
decreased
Richness Number of species
decreased
Faith Phylogenetic diversity, takes into account phylogenetic distance of all taxa identified in a sample
decreased

Signature 1

Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Source: Figure 2A

Description: Differentially abundant taxa from the phylum to genus level were further analyzed between Con and GD groups by STAMP analysis using Welch’s t test (p < 0.05, q < 0.05).

Abundance in Group 1: increased abundance in Graves’ disease (GD)

NCBI Quality ControlLinks
Bacilli
Lactobacillales
Streptococcaceae
Streptococcus
Veillonella
Thomasclavelia

Revision editor(s): Aleru Divine

Signature 2

Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Source: Figure 2A

Description: Differentially abundant taxa from the phylum to genus level were further analyzed between Con and GD groups by STAMP analysis using Welch’s t test (p < 0.05, q < 0.05).

Abundance in Group 1: decreased abundance in Graves’ disease (GD)

NCBI Quality ControlLinks
Marinifilaceae
Peptostreptococcaceae
Christensenellaceae
Rikenellaceae
Oscillibacter
Odoribacter
Romboutsia
Roseburia
Eubacterium ventriosum
Ruminococcus
Ruminococcaceae bacterium UCG-002Ruminococcaceae bacterium UCG-002
Adlercreutzia
Flavonifractor
Christensenellaceae R7 groupChristensenellaceae R7 group
Lachnospira

Revision editor(s): Aleru Divine

Experiment 2


Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Differences from previous experiment shown

Subjects

Group 0 name Corresponds to the control (unexposed) group for case-control studies
Graves’ disease before treatment (GDT0)
Group 1 name Corresponds to the case (exposed) group for case-control studies
Graves’ disease after treatment (GDT3)
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Patients diagnosed with Graves’ disease (GD) 3 months after treatment.
Group 0 sample size Number of subjects in the control (unexposed) group
37
Group 1 sample size Number of subjects in the case (exposed) group
37

Lab analysis

Statistical Analysis

Alpha Diversity

Pielou Quantifies how equal the community is numerically
unchanged
Shannon Estimator of species richness and species evenness: more weight on species richness
unchanged
Richness Number of species
unchanged
Faith Phylogenetic diversity, takes into account phylogenetic distance of all taxa identified in a sample
unchanged

Signature 1

Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Source: Figure 2B

Description: Differentially abundant taxa from the phylum to genus level were further analyzed between GDT0and GDT3 groups by STAMP analysis using Welch’s t test.

Abundance in Group 1: increased abundance in Graves’ disease after treatment (GDT3)

NCBI Quality ControlLinks
Peptostreptococcaceae
Romboutsia
Lachnospira

Revision editor(s): Aleru Divine

Signature 2

Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Source: Figure 2B

Description: Differentially abundant taxa from the phylum to genus level were further analyzed between GDT0 and GDT3 groups by STAMP analysis using Welch’s t test.

Abundance in Group 1: decreased abundance in Graves’ disease after treatment (GDT3)

NCBI Quality ControlLinks
Bacilli
Lactobacillales
Carnobacteriaceae
Streptococcaceae
Tyzzerella
Streptococcus
Granulicatella

Revision editor(s): Aleru Divine

Experiment 3


Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Differences from previous experiment shown

Subjects

Group 0 name Corresponds to the control (unexposed) group for case-control studies
Control group (Con)
Group 0 sample size Number of subjects in the control (unexposed) group
33

Lab analysis

Statistical Analysis

Alpha Diversity

Pielou Quantifies how equal the community is numerically
decreased
Shannon Estimator of species richness and species evenness: more weight on species richness
decreased
Richness Number of species
decreased
Faith Phylogenetic diversity, takes into account phylogenetic distance of all taxa identified in a sample
decreased

Signature 1

Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Source: Figure 2C

Description: Differentially abundant taxa from the phylum to genus level were further analyzed between Con and GDT3 groups by STAMP analysis using Welch’s t test.

Abundance in Group 1: increased abundance in Graves’ disease after treatment (GDT3)

NCBI Quality ControlLinks
Thomasclavelia

Revision editor(s): Aleru Divine

Signature 2

Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Source: Figure 2C

Description: Differentially abundant taxa from the phylum to genus level were further analyzed between Con and GDT3 groups by STAMP analysis using Welch’s t test.

Abundance in Group 1: decreased abundance in Graves’ disease after treatment (GDT3)

NCBI Quality ControlLinks
Christensenellaceae
Marinifilaceae
Eggerthellaceae
Muribaculaceae
Oscillibacter
Odoribacter
Christensenellaceae R-7 groupChristensenellaceae R-7 group
Coprococcus
Enterobacter
Klebsiella
Desulfovibrio
Ruminococcaceae bacterium UCG-002Ruminococcaceae bacterium UCG-002
Flavonifractor
Adlercreutzia
metagenome

Revision editor(s): Aleru Divine

Experiment 4


Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Differences from previous experiment shown

Subjects

Group 0 name Corresponds to the control (unexposed) group for case-control studies
Graves’ disease before treatment (GDT0)
Group 0 sample size Number of subjects in the control (unexposed) group
37

Lab analysis

Statistical Analysis

Statistical test
LEfSe
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
No
LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
3

Alpha Diversity

Pielou Quantifies how equal the community is numerically
unchanged
Shannon Estimator of species richness and species evenness: more weight on species richness
unchanged
Richness Number of species
unchanged
Faith Phylogenetic diversity, takes into account phylogenetic distance of all taxa identified in a sample
unchanged

Signature 1

Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Source: Figure 5C

Description: LEfSe analysis shows bacterial taxa significantly enriched in the GDT0 (red) or GDT3(green) groups. Taxonomic cladogram and linear discriminant analysis (LDA) scores show differences among taxa between GDT0 and GDT3. Only taxa meeting a significant LDA threshold value of >3 are shown.

Abundance in Group 1: increased abundance in Graves’ disease after treatment (GDT3)

NCBI Quality ControlLinks
Peptostreptococcaceae
Intestinibacter
Terrisporobacter

Revision editor(s): Aleru Divine

Signature 2

Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Source: Figure 5C

Description: LEfSe analysis shows bacterial taxa significantly enriched in the GDT0 (red) or GDT3(green) groups. Taxonomic cladogram and linear discriminant analysis (LDA) scores show differences among taxa between GDT0 and GDT3. Only taxa meeting a significant LDA threshold value of >3 are shown.

Abundance in Group 1: decreased abundance in Graves’ disease after treatment (GDT3)

NCBI Quality ControlLinks
Granulicatella
Carnobacteriaceae
Bacilli
Lactobacillales

Revision editor(s): Aleru Divine

Experiment 5


Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Differences from previous experiment shown

Subjects

Group 0 name Corresponds to the control (unexposed) group for case-control studies
Graves’ disease without hepatic impairment (GDN)
Group 1 name Corresponds to the case (exposed) group for case-control studies
Graves’ disease with impaired liver function before treatment (GDH)
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Patients with confirmed Graves’ disease (GD) and impaired liver function before treatment (GDH)
Group 0 sample size Number of subjects in the control (unexposed) group
47
Group 1 sample size Number of subjects in the case (exposed) group
18

Lab analysis

Statistical Analysis

Statistical test
Welch's T-Test
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
Yes
LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
Not specified


Signature 1

Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Source: Figure 4A

Description: Differentially abundant taxa from the phylum to genus level were further analyzed between GDH and GDN subgroups by STAMP analysis using Welch’s ttest (p < 0.05, q < 0.05).

Abundance in Group 1: increased abundance in Graves’ disease with impaired liver function before treatment (GDH)

NCBI Quality ControlLinks
Coprococcus

Revision editor(s): Aleru Divine

Signature 2

Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Source: Figure 4A

Description: Differentially abundant taxa from the phylum to genus level were further analyzed between GDH and GDN subgroups by STAMP analysis using Welch’s ttest (p < 0.05, q < 0.05).

Abundance in Group 1: decreased abundance in Graves’ disease with impaired liver function before treatment (GDH)

NCBI Quality ControlLinks
Pseudomonadota
Gammaproteobacteria
Enterobacterales
Enterobacteriaceae
Lactobacillaceae
Weissella

Revision editor(s): Aleru Divine

Experiment 6


Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Differences from previous experiment shown

Subjects

Lab analysis

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
raw counts
Statistical test
LEfSe
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
No
LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
3


Signature 1

Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Source: Figure 4B

Description: LEfSe analysis shows bacterial taxa significantly enriched in the GDH (red) or GDN(green) groups. Taxonomic cladogram and linear discriminant analysis (LDA) scores show differences among taxa between GDH and GDN. Only taxa meeting a significant LDA threshold value of >3 are shown.

Abundance in Group 1: increased abundance in Graves’ disease with impaired liver function before treatment (GDH)

NCBI Quality ControlLinks
Ruminiclostridium
Eubacterium ventriosum
Atopobiaceae
Olsenella
Candidatus Gastranaerophilales
Ruminococcaceae bacterium UCG-002Ruminococcaceae bacterium UCG-002

Revision editor(s): Aleru Divine

Signature 2

Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Source: Figure 4B

Description: LEfSe analysis shows bacterial taxa significantly enriched in the GDH (red) or GDN(green) groups. Taxonomic cladogram and linear discriminant analysis (LDA) scores show differences among taxa between GDH and GDN. Only taxa meeting a significant LDA threshold value of >3 are shown.

Abundance in Group 1: decreased abundance in Graves’ disease with impaired liver function before treatment (GDH)

NCBI Quality ControlLinks
Bacilli
Enterobacterales
Gammaproteobacteria
Lactobacillaceae
Lactobacillales
Pseudomonadota
Weissella

Revision editor(s): Aleru Divine